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Legends for figures 
Figure 1: Observed caffeine concentrations in blood as a function of postnatal age. Joined points 
indicate observations belonging to a same individual . 
Figure 2: Directed acyclic graph of the hierarchical statistical model. Symbols are: P, prior 
distributions; μθ, population mean parameters; ıθ, variance of population parameter; t, 
observation times; θ, unknown  parameters; A0 and M0 are respectively duration of gestation and 
body mass at birth (both supposed exactly measured); X, the administered treatment; Mt, the 
measured body mass at time t; cvM, the variation coefficient of masses and Yt, the measured 
caffeine concentration in blood. μcvM, and ıcvM are respectively for mean and variance of cvM 
parameters and ıc for the variance of the experimental measurements. F is the dynamic bio-
distribution model. Square nodes are for variables of known (or supposed known) values; circular 
nodes for unknown variables and the triangle represents a deterministic link. 
Figure 3: Data versus model predictions. The left and the right graphs respectively concern body 
masses and caffeine concentrations in blood for individuals of the training set. On the right side 
graph, each line segment describes the 90%-credibility interval associated to the corresponding 
prediction. The 90%-crediblity intervals have been plotted using ıc value of the maximum 
posterior vector. 
Figure 4: Caffeine concentration in blood (left) and body masses (right) as a function of time. 
Predictions have been calculated for one subject of the training set (Subject 9) and one subject of 
the test set (Subject 2). Means of the predictions are in bold lines, and the corresponding 90%-
credibility intervals are plotted with thin lines. Data are represented by dots. Note that 90%-
credibility interval of the predicted masses is not represented for the subject of the training set 
(subject 9) as it is very thin. 
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Figure 5 : Relative residuals for caffeine concentration as a function of postnatal age. Four 
different models are represented: Thomson et al. [1] (triangles), Lee et al. [2] (squares), Falcao et 
al. [3] (empty circles) and the one we propose (plain circles). Relative residuals correspond to the 
relative differences between test set data points and mean caffeine concentration predictions 
obtained by Monte Carlo simulations. 
Figure 6:  Body mass predictions as a function of the time for patient 31. The 5%, and 95% 
quantiles of predictions are plotted using gray lines, the mean of predictions using dark bold 
lines. Data are represented by the dots. Panel A shows the predicted masses  calculated from the 
original posterior-sampled parameters, using the covariates of the patient at birth, only. 
Predictions of panel B use, in addition, body mass data via the updated posterior parameters 
obtained by a particle algorithm. 
Figure 7: Caffeine concentration predictions as a function of time for patient 31. The 5% and 
95% quantiles of predictions are plotted using thin lines, the mean of predictions using bold lines. 
The data point is represented by dot. Panel A shows the predicted caffeine concentration in blood 
calculated from original posterior sampled parameters and using only the covariates of the 
patient. Predictions of panel B and C are performed using the posterior parameters updated via a 
particle algorithm. In panel B, only data masses are used for parameter updating while only 
measured caffeine concentration is used to update predictions in panel C. 
Figure 8: Histograms of the marginal posterior distributions of the population elimination model 
parameters. Top row graphs give the marginal distributions of the original posterior. Bottom row 
darker histograms give the marginal updated distributions, using one caffeine concentration data 
point for subject 31. Bottom row unfilled histograms recall the original posterior. 
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Abstract 
Background: Caffeine treatment is widely used in nursing care to reduce the risk of apnea of 
premature neonates. To check the therapeutic efficiency of the treatment against apnea, caffeine 
concentration in blood is an important indicator. The present study aims at building a 
pharmacokinetic model as a basis for a medical decision support tool. Methods: A new dynamic 
pharmacokinetic model is proposed to predict caffeine disposition in premature neonates. Time 
dependence of physiological parameters is introduced to describe rapid growth of neonates. To 
take into account the large variability in the population, the pharmacokinetic model is embedded 
in a population structure. The whole model is inferred within a Bayesian framework. To update 
caffeine concentration predictions as data of an incoming patient are collected, we propose a fast 
method such it can be used in a medical context. This involves the sequential updating of model 
parameters (at individual and population levels) via a stochastic particle algorithm. Results: Our 
model provides better predictions than the ones obtained with models previously published. We 
show through an example that sequential updating improves predictions of caffeine concentration 
in blood (reduce bias and length of credibility intervals.) The update of the pharmacokinetic 
model using mass and caffeine concentration data is studied. It shows how informative caffeine 
concentration data are in contrast to mass data. Conclusion: This study provides the 
methodological basis to anticipate caffeine concentration in blood, after a given treatment if data 
are collected on the treated neonate or not. 
 
Keywords: Pharmacokinetic compartmental model, population model, Bayesian inference, 
MCMC algorithms, particle algorithms, caffeine, neonates 
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Introduction 
Premature neonates suffer from various physiological deficiencies due to their immaturity at 
birth. In particular, they can suddenly stop breathing (apnea) spontaneously and quite 
frequently[4]. To reduce the occurrence of apneas, a caffeine treatment is often administered to 
premature neonates[5-7]. This treatment may last several weeks and can induce various secondary 
effects (on ventilation, sleep, metabolism, weight, glomerular filtration, etc.)[8-12]. Unfortunately, 
pediatricians have little knowledge about the actual occurrence of these effects, which appears to 
be widely variable from an individual to another. To balance treatment benefits and adverse 
effects, pediatricians try to keep caffeine blood concentration within a ``therapeutic" interval. 
This is checked via blood sampling. Since sampling blood causes trauma on such fragile infants, 
the number of blood samples is limited. Therefore, it is not possible to collect extensive 
information on caffeine concentration time course in a given patient and pediatricians refer to a 
standard protocol of administration[13, 14]. In doing so, they control treatments or times to sample 
``on average" in the patients' population. The aim of this paper is to define a PK model to be used 
as a basis for a medical decision tool to help pediatricians in individualizing caffeine 
administration. The developed PK model allows the predictions of caffeine time-course in a new 
patient for whom only easily collected covariates (duration of gestation and body mass at birth), 
and possibly, a few caffeine concentration data would be available. For this, we need to take 
advantage of all available information: data extracted from medical files, pediatricians' 
experience and published data on neonate physiology and caffeine population pharmacokinetics[1-
3]
. In this context, a Bayesian approach is efficient, as it allows an easy aggregation of such 
widely different and uncertain information sources[15-17] and naturally allows sequential learning.  
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To describe caffeine concentration in blood, a compartmental PK model which is an extention of 
the one proposed by Amzal et al. [18] , is proposed. As caffeine is hydrophilic and distributes in 
body water[19], our pharmacokinetic model has only one compartment. Its main parameters are 
the volume of distribution and the caffeine clearance. Moreover, as volume of distribution 
(depending on the amount of total body water) and metabolism change significantly during the 
few weeks of the treatment[20-22], we propose a dynamic model with time-dependent parameters. 
To take into account inter-individual variability, a hierarchical population model is defined and 
calibrated using historical data.  
As caffeine elimination is widely variable in infant populations[1-3], a more efficient PK model 
need to integrate new information on the treated patient. We show here how caffeine 
concentration predictions of the treated patient can be updated by running a particle algorithm 
using recorded body mass and/or caffeine concentration data. The proposed algorithm has the 
advantage to update both individual and population parameters on the basis of new individual 
data. Therefore there is no need to re-perform time-consuming calibration process to estimate 
new population parameters when incorporating this new information.  
To our knowledge, any tool for caffeine dose individualization is not used in pediatric services, 
until now. Even if methods for dose individualization have been proposed in the literature for 
other drugs[23-25] none has been applied to caffeine dosing. We show here how a population 
pharmacokinetic model can be calibrated using a particle algorithm in order to guide individual 
caffeine dosing in a reasonable time. Formal optimization of the treatment is not treated; we refer 
to Amzal et al.[18] and references therein for details on that question. 
 
In the present study, we start by the modeling of the caffeine bio-distribution, explaining how 
physiological parameters evolve with time. The following section is devoted to defining the 
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statistical model, to quantify sources of uncertainty. It also describes the Bayesian framework in 
which the inference problem is casted, recalling its principle and defining the chosen prior 
distributions. The next section details the model checking and model adequacy procedures used. 
We demonstrate, in the last section, how the model predictions can be sequentially updated with 
incoming data on new treated patients, and how this can be used for designing a medical decision 
support software. Finally, this approach and its results are discussed and put in perspective. 
Methods 
Pharmacokinetic Data 
The pharmacokinetic data come from medical files of 35 neonates treated in the Neonatal Unit 
and Intensive Care of the Pediatric Department of the Hospital of Amiens (France). These files 
are the only available in the set of medical files of the neonates admitted in the nursing care 
department during years 1998, 1999 and 2003. Files were pre-selected such they meet the 
following requirements: 
- contain at least one caffeine concentration measurement, 
- the treatment lasts 3 days at least, 
- the treatment goes at least until the post  conceptional age of the neonates is 35 weeks. 
 
The typical treatment administered to neonates consists of a charging injected dose of 20 mg/kg 
possibly spread out on the first two days, then a regular oral dose of 5 m/kg every day from the 
third day. The treatment usually lasts until the post conceptional age of the neonates reaches 35 
weeks. Naturally, these doses could have been modified by the pediatricians for clinical reasons. 
Observed concentrations of caffeine in blood were collected as requested by the physician. It 
does not exist any sampling scheme (see Figure 1). 
9 
[Figure 1 about here] 
For each patient, the extracted data Yt consisted of one to four concentrations of caffeine 
measured in blood after specific treatment X (timing, injected concentration or quantity given per 
os,) and measured daily body masses, Mt. An example of collected data (for two patients) is given 
in Figure 4; the observed caffeine concentrations in blood for all patients are represented on 
Figure 1. Covariates such as duration of gestation A0 and body mass at birth M0 were also 
recorded. These data are available upon request. 
 
The average of the body masses at birth for our neonates population (N=35) is 1.34 kg with a 
standard deviation of 0.35 kg. The smallest recorded masse at birth is 0.660 kg while the largest 
is 2.170 kg. The duration of gestation of these premature neonates is 29.1 weeks long on average 
(with a standard deviation of 2.1 weeks and a range of [23, 32] weeks of gestation). 
A Dynamic Model of Caffeine Biodistribution in PrematureNeonates 
One-Compartment Caffeine PK Model 
According to published pharmacokinetic studies[1-3], caffeine distribution in the body is well 
described by a one-compartment model[19]. The body is therefore modeled by one homogeneous 
compartment of volume V(t) at time t. Note that the time origin (t=0) corresponds here to birth 
time. Caffeine is eliminated from the central compartment with clearance CL(t).  The time-course 
of caffeine concentration c(t) (in mg/L) is therefore described using a first-order elimination. 
Input drug is modeled as an IV bolus using a zero-order absorption even in case of oral dosing 
(the assumption here is that absorption is very rapid). This assumption is made because necessary 
data to identify absorption rate are incomplete. 
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Body Mass Model 
From simple examination of the body mass data, it appears that the growth of premature neonates 
can be, in a first approximation, divided into two distinct periods. The body mass decreases 
during the first period of length Ĳ, while it subsequently increases during the second period. We 
propose linear relationships to describe that variation during the two periods. These functions 
depend on the covariates M0 (body mass at birth), A0 (post-conceptional age at birth supposed 








where α1 and α2 are the slopes of the straight line respectively decreasing and increasing of each 
phases. MĲ corresponds to the body mass at Ĳ ( 10MM ). 
Volume of Distribution Model 






where f25 is defined as the ratio of the distribution volume over body mass at  post-conceptional 
age 25 weeks (time T25) and fĲ is the value of that ratio at time Ĳ ( M
Vf )( ). ȕ is the slope of the 






The slope ȕ is set such as the ratio volume over mass at post-conceptional age 25 weeks is f25 and as the 
ratio volume over mass at Ĳ is fĲ. As the degree of plasma protein binding is quite low for caffeine[26] , the 
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volume of distribution is assumed comparable to total body water. In this case, f25 and fĲ are approximately 
equal to fraction of water at time T25 and Ĳ. 
 
Clearance Model 
Several authors showed an increase in elimination of caffeine with postnatal age[21, 27, 28]. 
According to all of them, caffeine elimination increases as a function of time and reaches a 
plateau after 3 to 4.5 months. Taking into account the duration of treatment (less than two months 
in general), we only modeled the first period and assumed that caffeine clearance increases 
linearly with time with a slope parameter γ and a constant at origin (t=0) CL0: 
.)( 0 tCLtCL  
Statistical Model 
The statistical model quantifies both uncertainties (on data measurements as well as modeling) 
and sources of variability. Data measurements as well as modeling and intra-individual variability 
errors are taken into account by using a measurement error model. To model uncertainty on 
parameters and their variability, probability distributions are used. Inter-individual variability is 
quantified in the framework of a population model[29, 30] by estimating its population parameters. 
Given the above bio-distribution model, the caffeine concentration in blood of a given patient is 
conditioned by the covariates M0 and A0 and the parameter vector ).,,,,,,( 02521 CLff  
Measurement Error Model 
The caffeine concentration in blood actually observed is affected by measurement errors which 
are assumed to be independent and log-normally distributed with a geometric mean of one and a 
geometric standard deviation ıc. Likelihood is then given by: 
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cXFNY )),,(log(~)log(  
where the function F corresponds to the PK model described above.  
A normal distribution (with zero mean and standard deviation ıM) measurement error model is 
also specified for body masses Mt: 
MtMNtM ),(~)(  
To take into account inter-individual variability of body masses (due, for example, to urinary 
excretion), the standard deviation of measured body masses has been considered as individual-
specific. It has been chosen as depending on the body mass of the neonate and on the individual 
parameter cvM: 
tMM Mcv  
Population Model 
The pharmacokinetic model has been embedded in a population model which considers that each 
subject parameter values θ are drawn from a statistical distribution G with given population mean 
μθ and variance ıθ (Figure 2). 
[Figure 2 about here] 
The proposed population model has two major components: the individual and the population 
levels. At the individual level, parameters θ are assumed to be normally or log-normally 
distributed (see Table I) with population means μθ and standard deviations ıθ. Truncation bounds 
of the distributions are set on the basis of the limits for plausible values. For each subject, the 
expected values of body mass and caffeine concentration in blood are a function F of 
administration X, depending on parameter θ, and the individual's covariates. At the population 
level, cvM is assumed to be distributed according to a truncated normal distribution with mean 
μcvM and standard deviation ıcvM (Table I).  
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 [Table I about here]  
Bayesian Inference via MCMC 
The Bayesian framework 
The population model described above is fitted to observed data, Yt, with Bayesian techniques[16, 
17]
. The Bayesian approach yields a sample θ of parameter values from their joint posterior 
distribution. From Bayes' theorem, the joint posterior distribution of parameters is proportional to 
the prior distributions of parameters multiplied by the data likelihood. The posterior is then an 
update, using collected data, of what it is known about parameters prior to the experiment. 
Prior Distribution 
The first step of the Bayesian approach consists in defining prior distributions that quantify the 
information coming from pediatricians expertise or from the scientific literature. Expertise of 
clinicians is then entered in the model through its structure and through the use of prior 
distributions parameters. Prior distributions on population parameters and their associated 
parameters are summarized in Table I. On the basis of available information, we specify a prior 
that covers the range of value that is deemed reasonable for each parameter. When we deal with 
mean parameters, we use truncated normal or uniform distributions as prior while for standard 
deviation parameters truncated lognormal or loguniform laws are used. For standard deviations, 
lognormal prior distributions are chosen when little prior knowledge about the parameter is 
available. For parameters on which no prior information is found, loguniform distribution is used. 
This distribution is preferred to the more standard Inverse Gamma distribution since it does not 
require to define mean and variance (as Inverse Gamma does) and only uses truncation bound. 
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For parameters related to body mass (α1, α2, Ĳ), priors are elicited[31-33] by encoding the 
pediatricians' knowledge. From their experience, neonates loose, on average about 25g/day 
during between the 3 to 20 first days, then gain bout 25g/day. This is used to build priors on 
,,
211
. Information on ,,
211
, are less easily elicited and rather flat priors are 
used.  
Since the degree of plasma protein binding is quite low for caffeine, we assume that the ratio 
volume over mass is approximately equal to fraction of body water. Thus, for f25 and fĲ, priors are 
proposed after referring to the percentage of water in body reported by the International 
Commission on Radiological Protection[20]. For parameters related to clearance, CL0 and γ, prior 
distributions are defined after re-parameterization of values from the literature[1-3]. Globally, all 
the previous studies agree and give the same magnitude order for the mean of the clearance at 
birth, 
0CL  (estimated between 0.006 and 0.03 L/h with an estimated standard deviation around 
0.003) and for the shape of temporal evolution of clearance (estimated between 1e-6and 5e-5 
with an estimated standard deviation around 3e-6). We have chosen mean of 
0CL and such 
they are a compromise between the published studies. To be not too restrictive and to take into 
account possible differences between studied populations, standard deviations are chosen a bit 
higher than those estimated in the literature. Population variance of clearance parameters ( 2
0CL  
and 2 ) are assigned prior distributions truncated between 1.1 and 3 corresponding to a 
population variability comprised between 10 and 300%: less than10 % of variability for a 
clearance parameter in the population seems incredible and 300% seems large enough since inter-
individual variability of caffeine clearance was estimated to be around 80% for adults [34] and is 
likely a bit larger for neonates. 
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Use of data for model calibration and adequacy checking 
The data are used to calibrate (fit), check and assess adequacy of the model. The adopted 
approach for model adequacy checking is cross-validation [35, 36]. To that effect, data files are 
divided into two groups: the training set and the test set.  
We start with the training set for model calibration (estimation of the different parameters) and 
checking the fits. Then, next we use the calibrated model to check its adequacy with respect to 
the test set. We also perform another evaluation of the model which consists in calculating the 
percentages of caffeine concentration and body mass data points from the test set falling within 
different credibility intervals for predictions. The results of these tests are discussed further 
below.  
Both sets of data are formed by a random binomial assignment with parameters equal to (p=1/3, 
N=35). Twenty-four medical files are drawn for the training set (calibration and checking the fits) 
and the other eleven files are assigned to model adequacy checking (test set). 
This process allows us to validate the model. Once this is done, we recalibrate the model using 
the full data set (35 subjects) to take into account all available information in our prediction 
procedure. This recalibration step gave what we call in the sequel, original posterior distribution. 
Model Calibration via MCMC 
We assessed the model parameters by sampling their values from the joint posterior distributions 
of all population and individual parameters, using the data from the 24 training set subjects. For 
this, we used Markov Chains Monte-Carlo simulations[37, 38] (Metropolis-Hastings sampler) 
performed by MCSim software[39] version 5.0.0. After 40,000 iterations of 3 parallel Markov 
chains, their convergence is checked by calculating the Gelman and Rubin Rˆ  ratio on the 20, 000 
last iterations[16]. The highest Rˆ  computed is 1.12, showing that all chains had approximately 
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converged. To get a sample from the targeted posterior distribution, we took one in 10 vector out 
additional 20,000 iterations of each chain after convergence checking (iteration 40,000 to 60,000) 
leading to a posterior sample of 6,000 parameter vectors. Running the three MCMC chains took 
about one day (on a pentium 4, microprocessor PC 2.8GHz). 
Sequential Updating 
For an incoming subject (just after birth), parameters can be guessed on the basis of population 
distribution (i.e., by sampling from those distributions). However, when data are collected on a 
subject during treatment, the parameters for that individual can be updated. For parameter 
updating, it is possible to re-perform the calibration process described above using all available 
data including the newly recorded ones. This involves re-running Markov chains. But this 
procedure is not applicable in practice by pediatricians because it is time-consuming. Thus, we 
propose to apply a particle algorithm[40-43] to sequentially update the posterior (individual and 
population) parameter sample obtained by calibration (original posterior). Since they start from 
the original posterior rather than from the priors of Table I, calculations converge faster than the 
classical calibration procedure[44]. Individual parameters and population parameters can be jointly 
and quickly updated. Other alternative methods to standard MCMC calibration have been 
proposed (MAP Bayesian, Multiple Model, and Interacting Multiple Model)[29, 45] to update 
predictions of the new patient. Our method generalizes MAP approach (consider the whole 
distribution instead of maximum a posteriori) and allows the updating of population parameters 
which was not proposed with MM or IMM methods, to our knowledge. The updating of 
population parameters would allow predictions on another future patient using the information 
brought by the incoming one. 
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The proposed updating method assumes that a current sample is available and consists in few 
steps. Call (θ1, ..., θN) our original posterior sample of parameters, which approximate a 
distribution p(θ), and let's denote y the new coming data. Each θi is also called a "particle" in this 
framework. We want to transform our sample into an another one (of same size N) from p(θ|y). 
The detailed updating algorithm can be described as follows:  
 For each particle i=1..N, compute its normalized weight wi (as in the Sampling 









These weights are easy to compute since they take the form of likelihood terms 
normalized by the sum of all likelihood. 
 Resample N particles (θ’1, ..., θ’N) from (θ1, ..., θN) according to the multinomial 
distribution M(N,w1,...,wN) 
 To avoid degeneracy problems, enrich the sample using a Markov kernel Q whose 
stationary distribution is p(θ|y). For each i=1..N, we draw (θ’’1, ..., θ’’N) from 
(θ’1, ..., θ’N). By definition, this transforms an approximated sample (θ’1, ..., θ’N) from 
p(θ|y) into another sample (θ’’1, ..., θ’’N) from p(θ|y), but now richer (more diverse). This 
final sample is the updated parameter sample. 
A convenient choice for the Markov step Q is a Metropolis-Hastings move as used in standard 
MCMC [37, 38]. We chose a Metropolis-Hasting step with an independent sampler [48] in which 
candidates for population parameters are drawn from the original posterior sample and individual 





The MCMC-calibrated model has been first checked by analyzing the initial posterior vectors' 
sample (data not shown, see Table II for a summary of final posterior estimate). 
Means of mass model parameters μα1 and μαβ were quite well appraised a priori by the experts, 
but calibration has decreased the standard deviation of these two parameters. Premature neonates 
lose, on average, 30 grams per day until the end of the sixth day, then gain, in a second period, 23 
grams per day on average. Body mass loss and the length of time during which decrease occurs 
are quite variable between individual (around 40% for both). The values of body weight gain are 
less variable in this population (around 25%).  
Posterior means of the population parameters related to the volume of distribution (μf25  and μfĲ) 
are close to the priors. This is partly due to the very informative nature of the prior distribution 
for these two parameters. The mean of the volume-over-mass ratio in population is equal to 85% 
at post-conceptional age 25 weeks and 75% at time Ĳ. In parallel, calibration has increased 
knowledge on population variability (The CVs of ıf25 and ıfĲ decreased from 20% to 16.3% and 
15.3% respectively). 
On average, clearance at birth is about 0.3 L/day. For our neonates (mean body mass: 1.340 kg 
and mean distribution volume: 85% of mass), the half-life of caffeine is t1/2=2.6 days. Clearance 
at birth, CL0, and slope of the temporal linear evolution of clearance, γ, are quite variable in this 
population (CV of CL0 about 27% and CV of γ equal to 77%). 
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Model Fit Checking 
Figure 3 shows model-predicted values using the joint maximum posterior parameter vector 
versus their observed counterparts. 
[Figure 3 about here] 
The posterior sample gives quite a good fit to the body mass observations. The average of the 
relative errors for mass is about 0.1% with a minimum around -12.4% and a maximum of 14%. 
Predicted caffeine concentrations in blood are not that good; the relative error is 8.5% in average 
with a minimum and a maximum respectively equal to -108% and 48%. Figure 4 shows the 
average of predicted caffeine concentrations and body mass predictions over time, for one subject 
of the training set (Subject 9). As already observed on Figure 4, model predictions well describe 
the data. 
[Figure 4 about here] 
Model Adequacy assessment 
Using the posterior sample, for each patient of the test set, mean curve and 90%-credibility 
intervals for predictions of body mass and caffeine concentration have been constructed (from 
Monte Carlo simulations) as a function of time (Subject 2 is the only plotted on Figure 4). For all 
the subjects of the test set, most of the caffeine concentration data fall in the credibility interval 
and body masses data are well estimated. 
The empirical percentages of data points falling within different credibility intervals are close to 
the credibility percent coverage (last line of Table III), showing that the shapes of the statistical 
distributions chosen to model measurement errors are appropriate. The fact that observed 
percentages for caffeine concentration tend to be lower than the theoretical ones in the tails could 
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be explained by the small number of caffeine concentration data points available in the test set 
(N=21 for 11 subjects). 
Comparison of Predictions from Previously Published Caffeine PK Models 
Three population PK models for caffeine have been previously proposed [1-3]. Caffeine 
concentration predictions for data belonging to the test set are made using these three models. 
Two of these models (Lee's and Falcao's) cannot predict body masses of neonates. Using set body 
masses (as observed at birth, for example) would be very penalizing for these models, so we 
choose to use the actually measured body masses, which is to their advantage. Monte Carlo 
simulations are run on the basis of the published parameter distributions to obtain credibility 
intervals on caffeine concentration predictions. For each model previously proposed average 
mean square errors (AMSE) and percentages of adequacy data points falling in different 
``theoretical" credibility intervals are given in Table II. 
[Table II about here] 
Our model better assesses uncertainty on caffeine concentration predictions: observed 
percentages of data points falling in the ``theoretical" credibility intervals are better than those 
obtained with previous models. These models have higher bias or over-dispersion (higher AMSE) 





,Yobs observations and Y  the estimate) of each model 
are plotted against postnatal age on Figure 5. It appears that our model gives a systematic 
prediction error at early time point (between the third and the eighth day of treatment). This point 
is discussed further below. However, most of the times, the proposed model gives better mean 
predictions than the other models for this data set. 
[Figure 5 about here] 
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Recalibration 
Again, three chains of 60, 000 iterations are run. One out of 10 of the last 40, 000 simulations of 
the three chains are recorded, yielding 12, 000 parameter sets. The Gelman-Rubin convergence 
diagnostic is less than 1.06 for all parameters. Using this very final sample, summary statistics for 
marginal posterior distributions of the population parameters are given in Table III. 
[Table III about here] 
Compared to posteriors obtained during the first calibration step (involving 24 subjects), the 
estimates have not drastically changed. Estimated statistics (means and standard deviations) of 
population parameters have changed by less than 33%. Parameters related to α1 and CL0 are the 
most significantly updated. μα1 is higher than previously; ıα1, μCL0 and ıCL0 have also increased. 
The estimated uncertainty of these parameters is slightly higher than after the initial calibration 
step. This is due to fact that the estimates of the individual parameters CL0 and α1 for the subjects 
of the test set are not fully centered in the previous population distribution.  
Sequential Updating of Predictions Using Sequential Incoming Data 
Obviously, more accurate predictions and credibility intervals would arise from taking into 
account the incoming data (body masses, blood samples, etc.) about subjects as they are clinically 
followed. This sequential update can easily be performed by correcting the previous posterior 
distributions using the new data. Since this update would not induce a drastic change, it is not 
necessary to run new MCMC chains. We demonstrate here the use of an efficient way to do it via 
particle methods[40].  
Let us illustrate the method through an example. Sequential updating is performed for patient 31 
(of the test set). We examine how different kinds of data can improve caffeine concentration 
predictions. The update is first done using mass data, then using caffeine concentration data. The 
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update could also be done with both kinds of data (mass and caffeine concentration data); the 
procedure would be same. Performing update with body mass data and caffeine concentration 
data separately allows to illustrate how informative caffeine concentration data are in comparison 
with body mass data.  
Neonate 31 is born at A0=30 weeks, with body mass M0=1.575kg. The daily body masses were 
measured during the 9 first days of treatment (Figure 6). The update is implemented first on the 
basis of recorded mass, using an original posterior sample of size of 12,000. An updated 
parameters sample is then obtained.  
The updated posterior distributions for α1, α1 and Ĳ are more accurate than the initial guess. Body 
masses dramatically increase knowledge about the time evolution pattern of mass for the patient. 
Figure 6 shows, for that subject, the predicted masses generated from the original posterior 
sampled parameters (panel A) and the predictions generated from updated parameters (panel B). 
Masses are clearly much better predicted in panel B. This updating procedure took about sixty 
seconds (on a pentium 4, microprocessor PC 2.8GHz running Windows XP), whereas running the 
three chains of the calibration procedures took about one day. The proposed updating procedure 
is about 1500 time faster than MCMC initial calibration. 
[Figure 6 about here] 
It is interesting to see how update can improve caffeine concentration predictions. Caffeine 
concentration in blood was measured for this subject on the third day of treatment (c=5.2, mg/L). 
The predictions derived from the original posterior distribution are quite bad (Figure 7A) and the 
predictions obtained from updated sample using the only body mass data are not good either 
(Figure 7B). Whereas predictions for masses are much better after mass parameter updating 
(Figure 6), caffeine concentration predictions on Figure 7B seems unchanged (the distribution 
tails below 5%tile and above the 95%tile do change in fact).  
23 
The same updating method is then performed using only the caffeine concentration observation 
(Figure 7C). The concentration data now falls within the 90%-credibility interval and the mean 
estimate (9.7 mg/L) is also nearer the data after updating than before (17.6 mg/L). The 
concentration data is very informative relatively compared to the original posterior, especially on 
clearance, as expected. The gain on precision of predictions brought by the updating using 
caffeine concentration data can be measured by comparing the spread of the 90%-credibility 
interval on caffeine concentration predictions before and after the update. The mean range 
between the lower and the upper bounds of the credibility interval (respectively corresponding to 
the 5th and the 95th %tiles) is equal to 26.2 mg/L before updating, 25.9 mg/L after updating 
using mass data and has been reduced to 13.2 mg/L after updating using caffeine concentration 
data.  
[Figure 7 about here] 
CL0 marginal updated distribution for individual'31 has been transformed (in shape and mean) 
after updating (the mean of CL0 has changed from 0.017 to 0.033 and the standard deviation has 
staid around 0.008). On the other hand, Ȗ distribution has not been much revised (the average of Ȗ 
has changed from 1.043x10-5 to 1.087 x10-5 and the standard deviation from 0.889x10-5 to 1.020 
x10-5).  
An important concern is to decide when to update the distributions. It would not be optimal to do 
it every day, for example after each body weight measurement, because of the low sensitivity of 
caffeine elimination parameters to those measurements. A pragmatic general answer can be found 
in Chopin 2002 [40]. In our case, a reasonable choice might be to perform the updating as soon as 
the observed body mass goes out of the predictions' (90%) credibility interval. Moreover, since 
the caffeine concentration data are strongly informative, it seems that update should be done after 
each new caffeine concentration measurement. 
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The updating procedure improves predictions for an individual as new data are collected, and 
thus, allows to guide dosing for this particular patient taking into account all its physiological 
characteristics (given by the covariates and the data). At the same time, this procedure also 
updates the joint population parameters distributions since MCMC calibration produces samples 
from the overall joint distribution of population and individual parameters. Figure 8 shows 
histograms of the marginal updated distributions for population mean and standard deviation of 
CL0 and Ȗ. As only one caffeine concentration data point on one subject has been used to update 
these population parameters, their distributions have not drastically changed. σevertheless, μCL0 
and ıCL0  distributions have been slightly translated to the right after updating, corresponding to 
greater values. This is coherent with the high value of CL0 for that individual. On the other hand, 
ıȖ distributions before and after updating shows that ıȖ has been slightly reduced because the 
estimated Ȗ for the new subject is well centered with the original population distribution. 
[Figure 8 about here] 
Discussion and Perspectives 
The present study aimes at providing the methodological basis for a quantitative decision support 
software for pediatricians who would like to anticipate neonates' caffeine concentration in blood, 
for a given treatment. Fitting a population model to individual data allowed us to make 
predictions for new subjects, given their covariates at birth, and a sample of random vectors of 
parameters from the posterior population distribution. These simulations give an ``average 
prediction" for future caffeine concentrations during treatment, as well as credibility intervals for 
them. We present a fast and easy way to update those predictions on the basis of subject specific 
data on body mass and caffeine concentration in blood. 
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Three caffeine distribution population models have already been proposed[1-3]. Thomson et al.'s 
model assumes that clearance depends on body mass at birth and does not account for mass 
changes over time. Similarly, caffeine distribution volume is also assumed to stay constant during 
treatment period. Making predictions over weeks, in such a context, can be misleading since the 
physiological variable of the premature neonates change significantly during the first trimester of 
life. Falcao et al. and Lee et al.'s models consider parameters (clearance and volume) as dynamic 
but requires infant body mass values at the time at which caffeine concentration is to be 
predicted. Lacking a body mass model, such models cannot be used for predictions over several 
days or weeks. However, even with a perfect mass model (i.e. using actually measured body 
masses), these two models do not give predictions as good as those of our new model (see Figure 
5). Overall, the model we propose gives the best predictions for our neonate population. Two 
points need however to be stressed: 
 Its mean predictions are still quite far from some data points (7 over 21 relative residuals 
errors are over 50%) revealing that the model might still be improved. Moreover, relative 
residual errors show a trend with post-natal age. Predictions of all four models over 
estimates just after birth and underestimats after about 25 days of postnatal age (Figure 5). 
This implies the models are not able to capture all information contained in the data.  
 Our model works quite well with local (Amiens) neonates. We do not know if it would be 
the best at describing Thomson's, Lee's or Falcao's data. We would recommend for a new 
calibration when going to new populations. 
 The population variability in caffeine clearance is relatively large and is the cause of the 
relatively large width of credibility intervals for the caffeine concentration predictions. This 
actually reflects the daily reality met by physicians. Part of this variability might be explained by 
introducing covariates which have not been taken into account here (as caffeine or tobacco 
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maternal consummation during pregnancy, other administered treatment than caffeine, for 
example). 
Another improvement could concern the model itself, and more precisely the absorption model. 
We made the assumption that oral absorption is very rapid. This is questionable. Not describing 
precisely the absorption process could generate errors in predictions at early time points. Given 
that misspecification the model could over-estimates the speed of caffeine bioavailability after 
the third day (beginning of per os administration). This over-estimation could lead to an under-
dosing over that period. A first-order oral absorption model might be better in this situation. 
However, after about the eighth day, caffeine absorption by oral route seems more or less quite 
well represented with a zero-order absorption rate (see Figure 5). We also made some choices 
which could be reconsidered, such as the linear form for the temporal evolution of physiological 
parameters, or the relative error to model the intra-individual variability in the body mass. Non-
parametric modeling[49, 50] of population distribution could also be an interesting approach. Non-
parametric models would relax hypotheses on parameter distributions. They could allow 
identification, for example, of bimodal population distributions, which could help in determining 
new explanatory covariates.  
As different updating methods exist, it could be interesting to compare the different approaches 
of sequential updating (MAP Bayesian, Multiple Model, and Interacting Multiple Model). It 
would also be interesting to compare our method to other ones[23-25]  already proposed for dose 
individualization by applying them to caffeine dosing, for example.  
A therapeutic dosing support tool should incorporate a sequential updating procedure such as the 
one detailed before. Admittedly, our procedure needs to be tuned (jump function, number of 
particle)[40] but it is fast, automatic and can be programmed easily in a medical support tool 
(currently under development). The only requirement for the user is to enter the newly collected 
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data. The pediatrician does not need to know details of modeling or statistics. The therapeutic 
support tool would, then, give individualized predictions on the basis of information collected on 
the treated patient. The updating using caffeine concentration data can give better estimate (less 
biased) and as the same time, reduce the spread of credibility interval of caffeine concentration 
predictions (by around a factor 2, in our example). The proposed particle algorithm allows to 
quickly update individual parameters distribution. Moreover, population parameters distributions 
are updated simultaneously so that all available information from past or current patients will be 
available for any new subject entering the hospital.  
To validate the benefit of the use of such a pharmacokinetic tool, a clinical trial could be based on 
a judgement criteria including observed effects after the comparison of two patient groups: one 
receiving the usual dosing and another one for which the dosing is assisted by the software tool. 
Finally, this technique was applied to caffeine as a demonstration study but could also be applied 
to other drugs with a narrower therapeutic window. Indeed, that would be all the more useful. 
Drugs for which the target serum concentration is close to the concentration limit leading to 
severe adverse effects, would certainly benefit to this method since it allows a quick and 
individualized estimation of the drug concentration using a limited number of measurements. 
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Table I: Parameter distributions of our PK model. Summary of the parameter distributions at 
individual level of the PK model and population prior distributions used in the calibration 
process.  
Parameter (unit) Distribution Truncation bounds 
Individual level   
 α1 (kg/h) Normal (μα1, ıα1) [-5x10-3 ; 0] 
 α2 (kg/h) Normal (μαβ, ıαβ) [0 ; 3x10-3] 
 Ĳ (h) LogNormal1 (μĲ, ıĲ) [72 ; 480] 
 f25 (L/kg) LogNormal1 (μf25, ıf25) [0.8 ; 0.9] 
 fĲ (L/kg) LogNormal1 (μfĲ ;  ıfĲ) [0.7 ; 0.8] 
 CL0 (L/h) LogNormal1 (μCL0, ıCL0) [0  ; 0.06] 
 γ (L/h2) LogNormal1 (μȖ, ıȖ) [5x10-7  ; 10-4] 
 cvM (unitless) Normal (μcvM, ıcvM) [0.010; 0.100] 
Population level   
 μα1 (kg/h) Normal (-10-3 , 0.6x10-3) [-5x10-3 ; 0] 
 μαβ (kg/h) Normal (10-3 , 0.5x10-3) [0 ; 3x10-3] 
 μĲ (h) Uniform [72 ; 480] 
 μf25 (L/kg) Normal (0.85 , 0.05) [0.8 ; 0.9] 
 μfĲ (L/kg) Normal (0.75 , 0.05) [0.7 ; 0.8] 
 μCL0 (L/h) Normal (0.02 , 0.01) [0 ; 0.04] 
 μȖ (L/h2) Normal (5x10-6 , 5x10-6) [5x10-7  ; 10-4] 
 ıα1 LogNormal1 (0.4x10-3 , 2.96) - 
 ıαβ LogNormal1 (0.4x10-3 , 2.96) - 
 ıĲ LogNormal1 (1.32 , 2.30) [1.01 ; 2] 
 ıf25 LogNormal1 (1.183 , 1.22) [1.01 ; 2] 
 ıfĲ LogNormal1 (1.183 , 1.22) [1.01 ; 2] 
 ıCL0 LogUniform [1.1 ; 3] 
 ıȖ LogUniform [1.1 ; 3] 
 μcvM (unitless) Uniform [0.010 ; 0.100] 
 ıcvM Normal (0.030 , 0.020) [0.005 ; 0.100] 
 ıC Normal (1.105 , 0.1) [1.01 ; 2] 
1
 For LogNormal distributions, the parameters in parenthesis correspond to the geometric mean 
(exponential of the mean in log-space) and geometric standard deviation (exponential of the 
standard deviation in log-space).  
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Table II: Indicators to compare the existing PK models. Average mean square error (AMSE) 
and percentages of adequacy data points falling within the ``theoretical" credibility intervals 
given by various models. These data points concern caffeine concentration of the subjects 
belonging to the test set. 21 data points are available for caffeine concentration in blood. 
Model 
Nominal credibility interval coverage (%) 
AMSE 
40 50 80 85 90 95 
Thomson's et al. 4.8 4.8 33.3 33.3 38.1 38.1 1.358 
Lee's et al. 9.5 9.5 14.3 28.6 42.9 47.6 2.207 
Falcao's et al. 9.5 14.3 42.9 42.9 47.6 57.1 2.036 
New proposed model 48.2 52.4 61.9 71.4 81.0 81.0 0.411 
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Table III: Summary statistics for the ultimate (N = 35 subjects) marginal posterior 
distributions of the population parameters. 
 
Population parameters mean SD 2.5%tile 97.5%tile 
μα1  0.00101 0.000174 0.00129 0.000592 
μαβ  0.000948 4.21x10-5 0.000864 0.00103 
μĲ 130 15.9 96.3 159 
μf25 0.85 0.0215 0.808 0.892 
μfĲ 0.752 0.0213 0.708 0.793 
μCL0 0.0154 0.00183 0.0121 0.0192 
μȖ 8.45x10-6 2.43x10-6 4.02x10-6 1.35x10-5 
ıα1 0.000676 0.000146 0.000464 0.00103 
ıαβ 0.000237 3.19 x10-5 0.000185 0.000309 
ıĲ 1.6 0.145 1.38 1.93 
ıf25  1.21 0.2 1.0 1.69 
ıfĲ 1.21 0.199 1.01 1.7 
ıCL0 1.54 0.198 1.2 2 
ıȖ 1.91 0.456 1.17 2.86 
μcvM   0.0179 0.00462 0.0105 0.0269 
ıcvM 0.018 0.00332 0.012 0.025 

















































Figure 1: Observed caffeine concentrations in blood as a function of postnatal age. Joined points 
indicate observations belonging to a same individual. 
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Figure 2: Directed acyclic graph of the hierarchical statistical model. Symbols are: P, prior 
distributions; μθ, population mean parameters; ıθ, variance of population parameter; t, 
observation times; θ, unknown  parameters; A0 and M0 are respectively gestational age and body 
mass at birth (both supposed exactly measured); X, the administered treatment; Mt, the measured 
body mass at time t; cvM, the variation coefficient of masses and Yt, the measured caffeine 
concentration in blood. μcvM, and ıcvM are respectively for mean and variance of cvM parameters 
and ıc for the variance of the experimental measurements. F is the dynamic bio-distribution 
model. Square nodes are for variables of known (or supposed known) values; circular nodes for 
unknown variables and the triangle represents a deterministic link. 
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Figure 3: Data versus model predictions. The left and the right graphs respectively concern body 
masses and caffeine concentrations in blood for individuals of the training set. On the right side 
graph, each line segment describes the 90%-credibility interval associated to the corresponding 




Figure 4: Caffeine concentration in blood (left) and body masses (right) as a function of time. 
Predictions have been calculated for one subject of the training set (Subject 9) and one subject of 
the test set (Subject 2). Means of the predictions are in bold lines, and the corresponding 90%-
credibility intervals are plotted with thin lines. Data are represented by dots. Note that 90%-
credibility interval of the predicted masses is not represented for the subject of the calibration set 
(subject 9) as it was very thin. 
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Figure 5: Relative residuals for caffeine concentration as a function of postnatal age. Four 
different models are represented: Thomson et. al. [1] (triangles), Lee et. al. [2] (squares), Falcao et. 
al. [3] (empty circles) and the one we propose (plain circles). Relative residuals correspond to the 
relative differences between training set data points and mean caffeine concentration predictions 
obtained by Monte Carlo simulations. 
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Figure 6: Body mass predictions as a function of the time for patient 31. The 5 %, and 95 % 
quantiles of predictions are plotted using gray lines, the mean of predictions using dark bold 
lines. Data are represented by the dots. Panel A shows the predicted masses  calculated from the 
original posterior-sampled parameters, using the covariates of the patient at birth, only. 
Predictions of panel B use, in addition, body mass data via the updated posterior parameters 
obtained by a particle algorithm. 
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Figure 7: Caffeine concentration predictions as a function of time for patient 31. The 5 % and 95 
% quantiles of predictions are plotted using thin lines, the mean of predictions using bold lines. 
The data point is represented by dot. Panel A shows the predicted caffeine concentration in blood 
calculated from original posterior sampled parameters and using only the covariates of the 
patient. Predictions of panel B and C are performed using the posterior parameters updated via a 
particle algorithm. In panel B, only data masses were used for parameter updating while only 
measured caffeine concentration was used to update predictions in panel C. 
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Figure 8: Histograms of the marginal posterior distributions of the population elimination model 
parameters. Top row graphs give the marginal distributions of the original posterior. Bottom row darker 
histograms give the marginal updated distributions, using one caffeine concentration data point for subject 
31. Bottom row unfilled histograms recall the original posterior. 
 
